These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Are steroids required for induction therapy and relapses in lupus nephritis? Abud-Mendoza C; González-Amaro R Ann Rheum Dis; 2013 Dec; 72(12):e29. PubMed ID: 23942867 [No Abstract] [Full Text] [Related]
24. Mycophenolate mofetil in lupus nephritis. Ginzler EM; Aranow C Lupus; 2005; 14(1):59-64. PubMed ID: 15732290 [TBL] [Abstract][Full Text] [Related]
25. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. Ginzler EM; Dooley MA; Aranow C; Kim MY; Buyon J; Merrill JT; Petri M; Gilkeson GS; Wallace DJ; Weisman MH; Appel GB N Engl J Med; 2005 Nov; 353(21):2219-28. PubMed ID: 16306519 [TBL] [Abstract][Full Text] [Related]
26. Pharmacological therapy of lupus nephritis. Fine DM JAMA; 2005 Jun; 293(24):3053-60. PubMed ID: 15972568 [TBL] [Abstract][Full Text] [Related]
27. Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide. Contreras G; Tozman E; Nahar N; Metz D Lupus; 2005; 14 Suppl 1():s33-8. PubMed ID: 15803929 [TBL] [Abstract][Full Text] [Related]
28. [Treatment of lupus nephritis]. Novak S Lijec Vjesn; 2014; 136(7-8):215-9. PubMed ID: 25327009 [TBL] [Abstract][Full Text] [Related]
29. Mycophenolate mofetil as maintenance therapy for childhood-onset systemic lupus erythematosus patients with severe lupus nephritis. Kizawa T; Nozawa T; Kikuchi M; Nagahama K; Okudela K; Miyamae T; Imagawa T; Nakamura T; Mori M; Yokota S; Tsutsumi H Mod Rheumatol; 2015 Mar; 25(2):210-4. PubMed ID: 25159157 [TBL] [Abstract][Full Text] [Related]
30. [Allergo-immunology. Clinical immunology]. Chizzolini C Rev Med Suisse; 2012 Jan; 8(323):11-3. PubMed ID: 22303732 [TBL] [Abstract][Full Text] [Related]
34. Recent progress in the treatment of proliferative lupus nephritis. Chan TM Am J Med; 2012 Jul; 125(7):642-8. PubMed ID: 22608789 [TBL] [Abstract][Full Text] [Related]
35. [Mycophenolate mofetil for the treatment of lupus nephritis. The case of lupus nephritis--class IV according to WHO--treated with mycophenolate mofetil]. Suszek D; Wielosz E; Majdan M Ann Acad Med Stetin; 2010; 56 Suppl 1():91-4. PubMed ID: 21365951 [TBL] [Abstract][Full Text] [Related]
36. New treatment strategies for proliferative lupus nephritis: keep children in mind! Ranchin B; Fargue S Lupus; 2007; 16(8):684-91. PubMed ID: 17711908 [TBL] [Abstract][Full Text] [Related]
37. Long-term outcomes of lupus nephritis treated with regimens based on cyclophosphamide and mycophenolate mofetil. Prasad N; Kurian J; Agarwal V; Bhadauria D; Behera M; Yacha M; Kushwaha R; Agrawal V; Jain M; Gupta A Lupus; 2020 Jul; 29(8):845-853. PubMed ID: 32437258 [TBL] [Abstract][Full Text] [Related]
38. Lupus nephritis: where are we now? Lightstone L Curr Opin Rheumatol; 2010 May; 22(3):252-6. PubMed ID: 20305561 [TBL] [Abstract][Full Text] [Related]
39. Exploring new territory: considering the future. Schneider M Lupus; 2007; 16(3):221-6. PubMed ID: 17432111 [TBL] [Abstract][Full Text] [Related]
40. Induction therapy for active lupus nephritis: mycophenolate mofetil versus cyclophosphamide. Burchardi C; Schlöndorff D Nat Clin Pract Nephrol; 2006 Jun; 2(6):314-5. PubMed ID: 16932452 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]